Kuros, Baxter deal

Baxter returned rights to KUR-212, KUR-213 and KUR-112 to Kuros. Baxter gained rights to the programs under a 2005 deal to develop and commercialize tissue repair products that use Kuros' biologics and associated binding technology and Baxter's TISSEEL fibrin sealant. Baxter will retain rights to KUR-111, KUR-113 and KUR-211. Further terms were not disclosed (see BioCentury, Nov. 21, 2005). ...